Communication disorder
diseaseOn this page
Also known as communicative disorders
Summary
Communication disorder (MONDO:0002182) is a disease and 19 clinical trials. Top therapeutic interventions include rotigotine and ecopipam. A subtype of specific developmental disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 19
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | communication disorder |
| Mondo ID | MONDO:0002182 |
| MeSH | D003147 |
| DOID | DOID:2033 |
| NCIT | C2958 |
| SNOMED CT | 278919001 |
| UMLS | C0009460 |
| MedGen | 3549 |
| Is cancer (heuristic) | no |
Also known as: communicative disorders
Disease family
This is a subtype of specific developmental disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › developmental disorder of mental health › specific developmental disorder › communication disorder
Related subtypes (9): fetal alcohol spectrum disorder, oppositional defiant disorder, fetal nicotine spectrum disorder, stereotypic movement disorder, tic disorder, learning disability, developmental coordination disorder, conduct disorder, attention deficit-hyperactivity disorder
Subtypes (2): speech disorder, language disorder
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 19.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 15 |
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02909088 | PHASE2/PHASE3 | UNKNOWN | Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). |
| NCT00723151 | PHASE2 | COMPLETED | Effects of Intensity of Early Communication Intervention |
| NCT04937452 | PHASE2 | COMPLETED | Dopaminergic Therapy for Frontotemporal Dementia Patients |
| NCT04655937 | PHASE1 | COMPLETED | Wellbeing After Stroke (WAterS): Supporting Adjustment and Wellbeing After Stroke |
| NCT05741853 | Not specified | RECRUITING | Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia |
| NCT05872737 | Not specified | RECRUITING | FAB Programme for Parents of Children With NDD |
| NCT06086951 | Not specified | RECRUITING | Pai.ACT - An Artificial Intelligence Driven Chatbot Assisted ACT |
| NCT06337188 | Not specified | RECRUITING | Adaptive and Individualized AAC Phase II |
| NCT06546813 | Not specified | RECRUITING | Outcomes of ICT Assistive Technology in RehabiliTAtIoN Pathways |
| NCT07005596 | Not specified | NOT_YET_RECRUITING | Early Speaking Valve in Ventilator Weaning: Effects on Communication, Depression, and Quality of Life |
| NCT00001308 | Not specified | TERMINATED | Central Mechanisms in Speech Motor Control Studied With H215O PET |
| NCT01917864 | Not specified | COMPLETED | iPad Application to Treat Prosodic Deficits in Students With Communication Disorders |
| NCT02018614 | Not specified | UNKNOWN | International Validation Study Of The Algoplus Scale In Five Languages |
| NCT04217460 | Not specified | UNKNOWN | Intervention for Fluency Difficulty |
| NCT04247828 | Not specified | COMPLETED | Adaptive and Individualized AAC |
| NCT04377893 | Not specified | COMPLETED | Applying Eye-Gaze Assistive Technology for Children and Youth With Complex Needs |
| NCT05398900 | Not specified | COMPLETED | Validity and Reliability of Indonesian Translated Ages and Stages Questionnaires - Third Edition (ASQ-3) as a Screening Tool for Developmental Delay in 1-12 Months Old Children |
| NCT05980897 | Not specified | COMPLETED | Inner Speech and Naming Treatment for Individuals with Aphasia |
| NCT06262646 | Not specified | COMPLETED | Video-conferencing FACT for Young Children With Special Needs |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ROTIGOTINE | 4 | 1 |
| ECOPIPAM | 3 | 1 |
| CHEMBL104383 | 0 | 1 |
Related Atlas pages
- Drugs: Rotigotine, Ecopipam